Significance of performing 123I-metaiodobenzylguanidine myocardial scintigraphy at different times for the long-term prediction of cardiac events in patients with dilated cardiomyopathy

Nuclear Medicine Communications

Volumn 31, Issue 6, 2010, Pages 488-494

  Nakanishi, Rine ^a   Fujimoto, Shinichiro ^a   Utanohara, Yuko ^a   Takamura, Kazuhisa ^a   Inoue, Aritomo ^a   Yamashina, Shohei ^a   Namiki, Atsushi ^a   Yamazaki, Junichi ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

123I metaiodobenzylguanidine myocardial scintigraphy; Dilated cardiomyopathy; Long term prognosis

Indexed keywords

(3 IODOBENZYL)GUANIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IODINE 123; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FOLLOW UP; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE; HEART SCINTISCANNING; HUMAN; SCORING SYSTEM; ANALYSIS OF VARIANCE; FEMALE; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PROGNOSIS; SCINTISCANNING; TIME;

3-IODOBENZYLGUANIDINE; ADRENERGIC BETA-ANTAGONISTS; ANALYSIS OF VARIANCE; CARDIOMYOPATHY, DILATED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PROGNOSIS; TIME FACTORS;

EID: 77951721501     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283306f70     Document Type: Article

References (39)

1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355. (Pubitemid 26152713)
2. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Study Group. Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999; 353:2001-2007.
3. CIBIS-II investigators. The cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
4. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, et al.; and for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:2194-2199.
5. The CONCENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONCENSUS). N Engl J Med 1987; 316:1429-1435.
6. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
7. The SOLVD Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691.
8. Pitt B, Segal R, Martinez FA, Meuers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captoril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752.
9. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study-ELITE II. Lancet 2000; 355:1582-1587.
10. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
11. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al.; CHARM Investigators and Committees. Effect of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARMAlternative Trial. Lancet 2003; 362:772-776. (Pubitemid 37093917)
12. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
13. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33:471-477.
14. Nakata T, Miyamoto K, Doi A, Sasao H,Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998; 5:579-590.
15. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K, Ehime MIBG Heart Failure Study Investigators. Prognostic value of iodine-123- metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyaopathy. Jpn Circ J 2001; 65:155-160.
16. Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, et al. Iodine-123-metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995; 26:1594-1599.
17. Ogita H, Shimonagata T, Fukunami M, Kumagai K, Yamada T, Asano Y, et al. Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 2001; 86:656-660.
18. Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol 2003; 41:231-238.
19. Agostini D, Belin A, Amar MH, Darlas Y, Hamon M, Grollier G, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med 2000; 41:845-851. (Pubitemid 30266029)
20. Fujimura M, Yasumura Y, Ishida Y, Nakatani S, Kimamura K, Yamagishi M, et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail 2000; 6:3-10.
21. Lotze U, Kaepplinger S, Kober A, Richartz BM, Gottschild D, Figulla HR. Recovery of the cardiac adrenergic nervous system after long-term beta-blocker therapy in idiopathic dilated cardiomyopathy: assessment by increase in myocardial 123I-metaiodobenzylguanidine uptake. J Nucl Med 2001; 42:49-54.
22. Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, Nakano H, et al. Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of beta-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. Eur J Nucl Med Mol Imaging 2004; 31:1356-1361.
23. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1007; 38:1085-1089.
24. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Addition of valsartan to angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003; 44:884-890.
25. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005; 45:661-667.
26. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41:574-581.
27. Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, Nakano H, et al. Usefulness of meta-[123I] iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker trearment. Nucl Med Commun 2005; 26:97-102.
28. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996; 94:2285-2296.
29. Cohn JN, Ferrari R, Sharpe N, on behalf of International Forum on Cardiac Remodeling. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35:569-582.
30. Udelson JE. Ventricular remodeling in heart failure and the effect of b-blockade. Am J Cardiol 2004; 93:43B-48B.
31. Frigerio M, Roubina E. Drugs for left ventricular remodeling in heart failure. Am J Cardiol 2005; 96:10L-18L.
32. Doi M, Yano M, Kobayashi S. Propranol prevents the development of heart failure by restoring FKBP 12.6-mediated stabilization of ryanodine receptor. Circulation 2002; 105:1374-1379.
33. Reiken S, Wehrens XH, Vest JA, Barbone A, Klotz S, Mancini D, et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 2003; 107:2459-2466.
34. Kitaoka H, Matsumura Y, Yamasaki N, Kondo F, Furuno T, Doi Y. Long-term prognosis of patients with mildly dilated cardiomyopathy. Circ J 2002; 66:557-560. (Pubitemid 34733495)
35. Hori M, Sasayama S, Kitabatake A, Toyooka T, Handa S, Yokoyama M, et al.; MUCHA Investigators. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147:324-330.
36. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al., for the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346:1845-1853.
37. Saxon LA, De Marco T, Schafer J, Chatterjee K, Kumar UN, Foster E, for the VIGOR Congestive Heart Failure Investigators. Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation 2002; 105:1304-1310.
38. Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, et al.; Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effects of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003; 107:1985-1990.
39. McAlister FA, Ezekowitz JA,Wiebe N, Rowe B, Spooner C, Crumley E, et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004; 141:381-390.